PURPOSE: Sildenafil is an oral phosphodiesterase type 5 inhibitor that is a vasodilator used in the treatment of erectile dysfunction. Cyclic nucleotide-dependent vasorelaxation is associated with increases in the phosphorylation of the heat shock related protein 20 (HSP20). The purpose of this study was to determine if sildenafil-induced vasorelaxation is associated with increases in the phosphorylation of HSP20. MATERIALS AND METHODS: Peptides containing an 11 amino acid enhanced protein transduction domain (PTD) and the functional 13 amino acid sequence of HSP20 with a phosphoserine (PTD-pHSP20) were synthesized using F-MOC technology. Rings of porcine coronary artery were suspended in a muscle bath and sub-maximally contracted with serotonin. Increasing concentrations of sodium nitroprusside (SNP; 0.01-10 microM), sildenafil (0.01-100 microM), or PTD-pHSP20 (0.1-1.0 mM) were added to the baths and the percent relaxation was recorded. To determine if sildenafil-induced vasorelaxation was associated with increases in the phosphorylation of HSP20, rings of porcine coronary artery were untreated (control) or treated with SNP (10 microM) or sildenafil (100 microM) for 2, 5, and 10 min and then snap frozen. Extracted proteins were then separated using two-dimensional SDS-PAGE, transferred to a membrane, and probed for HSP20. RESULTS: Sildenafil induced vasorelaxation of pre-contracted coronary artery in a dose-dependent manner. Sildenafil-induced vasorelaxation was associated with an increase in the phosphorylation of HSP20. Transduction of peptide analogues of pHSP20 led to a dose-dependent relaxation of pre-contracted porcine coronary artery. CONCLUSIONS: These findings suggest that sildenafil-induced vasorelaxation is associated with increases in the phosphorylation of HSP20 and that transduction of phosphopeptide analogues of HSP20 is sufficient for relaxation of vascular smooth muscle.
PURPOSE:Sildenafil is an oral phosphodiesterase type 5 inhibitor that is a vasodilator used in the treatment of erectile dysfunction. Cyclic nucleotide-dependent vasorelaxation is associated with increases in the phosphorylation of the heat shock related protein 20 (HSP20). The purpose of this study was to determine if sildenafil-induced vasorelaxation is associated with increases in the phosphorylation of HSP20. MATERIALS AND METHODS: Peptides containing an 11 amino acid enhanced protein transduction domain (PTD) and the functional 13 amino acid sequence of HSP20 with a phosphoserine (PTD-pHSP20) were synthesized using F-MOC technology. Rings of porcine coronary artery were suspended in a muscle bath and sub-maximally contracted with serotonin. Increasing concentrations of sodium nitroprusside (SNP; 0.01-10 microM), sildenafil (0.01-100 microM), or PTD-pHSP20 (0.1-1.0 mM) were added to the baths and the percent relaxation was recorded. To determine if sildenafil-induced vasorelaxation was associated with increases in the phosphorylation of HSP20, rings of porcine coronary artery were untreated (control) or treated with SNP (10 microM) or sildenafil (100 microM) for 2, 5, and 10 min and then snap frozen. Extracted proteins were then separated using two-dimensional SDS-PAGE, transferred to a membrane, and probed for HSP20. RESULTS:Sildenafil induced vasorelaxation of pre-contracted coronary artery in a dose-dependent manner. Sildenafil-induced vasorelaxation was associated with an increase in the phosphorylation of HSP20. Transduction of peptide analogues of pHSP20 led to a dose-dependent relaxation of pre-contracted porcine coronary artery. CONCLUSIONS: These findings suggest that sildenafil-induced vasorelaxation is associated with increases in the phosphorylation of HSP20 and that transduction of phosphopeptide analogues of HSP20 is sufficient for relaxation of vascular smooth muscle.
Authors: Catherine M Dreiza; Padmini Komalavilas; Elizabeth J Furnish; Charles R Flynn; Michael R Sheller; Christopher C Smoke; Luciana B Lopes; Colleen M Brophy Journal: Cell Stress Chaperones Date: 2009-07-01 Impact factor: 3.667
Authors: Kleiton Augusto Santos Silva; Emily V Leary; T Dylan Olver; Timothy L Domeier; Jaume Padilla; R Scott Rector; Craig A Emter Journal: Am J Physiol Heart Circ Physiol Date: 2020-09-18 Impact factor: 4.733
Authors: Luciana B Lopes; Colleen M Brophy; Elizabeth Furnish; Charles R Flynn; Olivia Sparks; Padmini Komalavilas; Lokesh Joshi; Alyssa Panitch; M Vitoria L B Bentley Journal: Pharm Res Date: 2005-05-17 Impact factor: 4.200
Authors: Luciana B Lopes; Elizabeth J Furnish; Padmini Komalavilas; Charles R Flynn; Patricia Ashby; Adam Hansen; Daphne P Ly; George P Yang; Michael T Longaker; Alyssa Panitch; Colleen M Brophy Journal: J Invest Dermatol Date: 2008-09-11 Impact factor: 8.551
Authors: Ryan T Cameron; Ellanor Whiteley; Jon P Day; Anna I Parachikova; George S Baillie Journal: FEBS Open Bio Date: 2016-12-05 Impact factor: 2.693
Authors: Kristina V Tugaeva; Daria I Kalacheva; Richard B Cooley; Sergei V Strelkov; Nikolai N Sluchanko Journal: Sci Rep Date: 2019-10-18 Impact factor: 4.379